Endocrine Abstracts

AZP-3601, a long-acting PTH/PTHrP(1-36) analog, is a candidate new treatment option for hypoparathyroidism (HP). As compared to conventional PTH(1-34), AZP-3601 binds with higher affinity to the R0 conformation of the PTH-1 receptor, resulting in prolonged signaling and sustained elevations in blood calcium (Ca++) in vivo, despite a very short circulating half-life. We assessed whether repeated injection of AZP-3601 into TPTX rats at doses aimed to normalize serum C...